PURPOSE:Two nonoperative approaches (one without fluorouracil) using induction chemotherapy and then definitive chemoradiotherapy developed at two centers were compared in patients with localized esophageal cancer (LEC). The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405. PATIENTS AND METHODS: In a multi-institutional cooperative group setting, patients with LEC who had unresectable cancer, were unwilling to undergo surgery, or were medically unfit for surgery were randomly assigned to receive either induction with fluorouracil, cisplatin, and paclitaxel and then fluorouracil plus paclitaxel with 50.4 Gy of radiation (arm A) or induction with paclitaxel plus cisplatin and then the same chemotherapy with 50.4 Gy of radiation (arm B). Safety and survival rates were assessed. RESULTS: A total of 84 patients were randomly assigned (arm A, n = 41; arm B, n = 43), and 72 were assessable (arm A, n = 37; arm B, n = 35). The median survival time was 28.7 months for patients in arm A and 14.9 months for patients in arm B (18.8 months for patients in RTOG 9405). The 1-year survival rate of 75.7% in arm A was close to, but did not meet or surpass, the 77.5% goal. The 2-year survival rate was 56% for arm A and 37% for arm B. Grade 3 (arm A = 54%, arm B = 43%) and grade 4 toxicities (arm A = 27%, arm B = 40%) were frequent. Treatment-related death occurred in 3% of patients in arm A and 6% of patients in arm B. CONCLUSION: Both arms of RTOG 0113 were associated with high morbidity, and the study did not meet its 1-year survival end point.
RCT Entities:
PURPOSE: Two nonoperative approaches (one without fluorouracil) using induction chemotherapy and then definitive chemoradiotherapy developed at two centers were compared in patients with localized esophageal cancer (LEC). The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405. PATIENTS AND METHODS: In a multi-institutional cooperative group setting, patients with LEC who had unresectable cancer, were unwilling to undergo surgery, or were medically unfit for surgery were randomly assigned to receive either induction with fluorouracil, cisplatin, and paclitaxel and then fluorouracil plus paclitaxel with 50.4 Gy of radiation (arm A) or induction with paclitaxel plus cisplatin and then the same chemotherapy with 50.4 Gy of radiation (arm B). Safety and survival rates were assessed. RESULTS: A total of 84 patients were randomly assigned (arm A, n = 41; arm B, n = 43), and 72 were assessable (arm A, n = 37; arm B, n = 35). The median survival time was 28.7 months for patients in arm A and 14.9 months for patients in arm B (18.8 months for patients in RTOG 9405). The 1-year survival rate of 75.7% in arm A was close to, but did not meet or surpass, the 77.5% goal. The 2-year survival rate was 56% for arm A and 37% for arm B. Grade 3 (arm A = 54%, arm B = 43%) and grade 4 toxicities (arm A = 27%, arm B = 40%) were frequent. Treatment-related death occurred in 3% of patients in arm A and 6% of patients in arm B. CONCLUSION: Both arms of RTOG 0113 were associated with high morbidity, and the study did not meet its 1-year survival end point.
Authors: I I Schnirer; R Komaki; J C Yao; S Swisher; J Putnam; P W Pisters; J A Roth; J A Ajani Journal: Am J Clin Oncol Date: 2001-02 Impact factor: 2.339
Authors: Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Baruch Brenner; David H Ilson; Bruce D Minsky; Manjit S Bains; William Tong; Mithat Gonen; David P Kelsen Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544
Authors: Maryam B Lustberg; Tanios Bekaii-Saab; Donn Young; Gregory Otterson; William Burak; Abbas Abbas; Barbara McCracken-Bussa; Mark E Lustberg; Miguel A Villalona-Calero Journal: J Thorac Oncol Date: 2010-05 Impact factor: 15.609
Authors: Akihiro Suzuki; Lianchun Xiao; Yuki Hayashi; Homer A Macapinlac; James Welsh; Steven H Lin; Jeffrey H Lee; Manoop S Bhutani; Dipen M Maru; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani Journal: Cancer Date: 2011-03-31 Impact factor: 6.860
Authors: Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani Journal: Eur J Cancer Date: 2015-08-28 Impact factor: 9.162